Clinical Experience With Venetoclax‐Based Combinations for Relapsed/Refractory or MRD ‐Positive NPM1 ‐Mutated Acute Myeloid Leukemia

Documenti analoghi

• Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE‐A
  di: Naseema Gangat, et al.
  Pubblicazione: (2024)
• Therapeutic Targeting of the Activin Receptor Signaling Pathway: Proof of Concept in Myeloid Neoplasms
  di: Ayalew Tefferi, et al.
  Pubblicazione: (2025)
• Targeting anemia in myeloid neoplasms
  di: Naseema Gangat, et al.
  Pubblicazione: (2024)
• New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors
  di: Naseema Gangat, et al.
  Pubblicazione: (2024)
• The Hemojuvelin‐Hepcidin Axis as a Target for the Treatment of Anemia or Conversely Polycythemia
  di: Naseema Gangat, et al.
  Pubblicazione: (2025)